Patents Assigned to ORA, INC.
  • Patent number: 12048685
    Abstract: The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 30, 2024
    Assignee: Ora, Inc.
    Inventors: Mark B. Abelson, Peter Corcoran, Keith Lane
  • Patent number: 11246483
    Abstract: The present invention relates to an apparatus including a base, a hollow receiving element joined to the base, and at least one positioning attachment that positions an imaging device received by the hollow receiving element to capture an image of at least one eye of a user. The present invention also relates to a method of capturing at least one image of at least one eye of a user using the above described apparatus.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 15, 2022
    Assignee: Ora, Inc.
    Inventors: Richard Abelson, Mark B. Abelson, Endri Angjeli, Keith Lane
  • Publication number: 20210052582
    Abstract: Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Applicants: Portola Pharmaceuticals, Inc., ORA, Inc.
    Inventors: Anjali PANDEY, Matthew CHAPIN, Harold PATTERSON, Yung Yueh HSU, Mark ABELSON
  • Patent number: 10603303
    Abstract: The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 31, 2020
    Assignee: Ora, Inc.
    Inventors: Mark B. Abelson, Peter Corcoran, Keith Lane
  • Publication number: 20180252700
    Abstract: The present invention provides methods of identifying a subject as susceptible to treatment for an ocular disease or disorder. The present invention also provides methods of screening an agent for the treatment of an ocular disease or disorder. In certain embodiments, the ocular disease or disorder is dry eye disease.
    Type: Application
    Filed: October 6, 2017
    Publication date: September 6, 2018
    Applicant: Ora, Inc.
    Inventor: Mark B. Abelson
  • Publication number: 20180160902
    Abstract: The present invention relates to an apparatus including a base, a hollow receiving element joined to the base, and at least one positioning attachment that positions an imaging device received by the hollow receiving element to capture an image of at least one eye of a user. The present invention also relates to a method of capturing at least one image of at least one eye of a user using the above described apparatus.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Applicant: Ora, Inc.
    Inventors: Richard Abelson, Mark B. Abelson, Endri Angjeli, Keith Lane
  • Publication number: 20170258760
    Abstract: The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease.
    Type: Application
    Filed: January 27, 2017
    Publication date: September 14, 2017
    Applicant: Ora, Inc.
    Inventors: Mark B. Abelson, Peter Corcoran, Keith Lane
  • Patent number: 9027383
    Abstract: This is directed to systems, processes, machines, and other means that simulate blast waves from explosive events. The invention can make waveforms tailored to a user's preference to accurately model a variety of explosive events by utilizing a driver section and a transition section that have divergent geometries.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: May 12, 2015
    Assignee: ORA, Inc.
    Inventors: David V Ritzel, Steven Parks
  • Publication number: 20130042665
    Abstract: This is directed to systems, processes, machines, and other means that simulate blast waves from explosive events. The invention can make waveforms tailored to a user's preference to accurately model a variety of explosive events by utilizing a driver section and a transition section that have divergent geometries.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 21, 2013
    Applicant: ORA, INC.
    Inventors: David V. Ritzel, Steven Parks
  • Patent number: D737450
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 25, 2015
    Assignee: Ora, Inc.
    Inventor: Richard Abelson
  • Patent number: D875946
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 18, 2020
    Assignee: Ora, Inc.
    Inventors: Richard Abelson, Mark B. Abelson, Endri Angjeli, Keith Lane